{"id":787454,"date":"2023-10-02T14:32:05","date_gmt":"2023-10-02T18:32:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/"},"modified":"2023-10-02T14:32:05","modified_gmt":"2023-10-02T18:32:05","slug":"shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/","title":{"rendered":"SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm"},"content":{"rendered":"<div class=\"mw_release\">\n<p>PHILADELPHIA, Oct.  02, 2023  (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Prelude Therapeutics Inc. (NASDAQ: PRLD) (\u201cPrelude\u201d) on behalf of the company\u2019s investors.<\/p>\n<p>Since April 2023, shares of Prelude\u2019s common stock have declined in value from a trading price of over $8.00 per share to a current trading price of approximately $3.00 per share, a cumulative decline of <strong><em>over $5.00 per share, or 62% in value<\/em><\/strong>.<\/p>\n<p>The investigation seeks to determine whether the company\u2019s officers and\/or directors breached their fiduciary duties or violated the securities laws in connection with recent corporate actions.<\/p>\n<p>\n        <strong><br \/>\n          <em>Prelude stockholders are encouraged to contact Kaskela Law LLC<\/em><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <em> (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 \u2013 0750, or by email (<\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Erp-XkUYOPJlRoDOK9OH3cpAJYMjwYe90h97wAXLNfDC4XiooIdw6oD1kRbuVYZi5ENKxSRJw-4wH4iTYk0stgvSKdeBxr8bDyjGC4FyBXU=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em>skaskela@kaskelalaw.com<\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em> \/ <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MXz_XhGlby6AeaqRqfTCF50jcXaNhghn6zyIRfcMVcUQ6IuvAQgWA0YworOwazVKHnvLYcexy112DZy9YxnRvBmJKhZhdv0uwApQ9JKtBwI=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em>abell@kaskelalaw.com<\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em>) or online at <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sMNoFE1hngg4DbkEWsOiQeFcAklSFhnB6ZTeS-Fqi4JjUq2k0VFQI6aLhBzToD2Whj_Np7v32WssoK9hxqm8EDbfz438JVLBbGurTqS3h-tB1HjnYjzHq_686siSlTkpDmzXB-dL6BV7dto7ndbrQN3BCEL5nCeBU48fljfw1nQ=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em>https:\/\/kaskelalaw.com\/cases\/prelude-therapeutics\/<\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em> , for additional information about this investigation and their legal rights and options.<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger &amp; acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3Zn1aZ80_b1XxwhebSDoCN0IX3rOktrZlujmbLaB_JYDOyt94-zLK3FN2XwmkVYt-fWJ6Al3Y4KQLXH0UBP2oVQjcrd6RTlh4zpvPAIQmD8=\" rel=\"nofollow noopener\" target=\"_blank\">www.kaskelalaw.com<\/a>.<\/p>\n<p>\n        <strong>CONTACT:<\/strong>\n      <\/p>\n<p>\n        <strong>KASKELA LAW LLC<\/strong><br \/>\n        <br \/>D. Seamus Kaskela, Esq.<br \/>Adrienne Bell, Esq.<br \/>18 Campus Blvd., Suite 100<br \/>Newtown Square, PA 19073<br \/>(888) 715 \u2013 1740<br \/>(484) 229 \u2013 0750<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3Zn1aZ80_b1XxwhebSDoCLTQsd0PLiIdQWh19aIjUgFcNu9X25apvnVkND8KMy-DAMggKb9OSdUpBU-IRNBB4eualplRusbfSVPYAb6T64I=\" rel=\"nofollow noopener\" target=\"_blank\">www.kaskelalaw.com<\/a><\/p>\n<p>This notice may constitute attorney advertising in certain jurisdictions.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyNyM1ODUxNDQxIzIwOTk5MzU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDBlNThhMTEtZGM5ZS00YjhmLWFlZTctMzQ1MTlmY2M5ZDUzLTExMTE1MDY=\/tiny\/Kaskela-Law.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, Oct. 02, 2023 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Prelude Therapeutics Inc. (NASDAQ: PRLD) (\u201cPrelude\u201d) on behalf of the company\u2019s investors. Since April 2023, shares of Prelude\u2019s common stock have declined in value from a trading price of over $8.00 per share to a current trading price of approximately $3.00 per share, a cumulative decline of over $5.00 per share, or 62% in value. The investigation seeks to determine whether the company\u2019s officers and\/or directors breached their fiduciary duties or violated the securities laws in connection with recent corporate actions. Prelude stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 \u2013 0750, or by &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-787454","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Oct. 02, 2023 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Prelude Therapeutics Inc. (NASDAQ: PRLD) (\u201cPrelude\u201d) on behalf of the company\u2019s investors. Since April 2023, shares of Prelude\u2019s common stock have declined in value from a trading price of over $8.00 per share to a current trading price of approximately $3.00 per share, a cumulative decline of over $5.00 per share, or 62% in value. The investigation seeks to determine whether the company\u2019s officers and\/or directors breached their fiduciary duties or violated the securities laws in connection with recent corporate actions. Prelude stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 \u2013 0750, or by &hellip; Continue reading &quot;SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-02T18:32:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyNyM1ODUxNDQxIzIwOTk5MzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm\",\"datePublished\":\"2023-10-02T18:32:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/\"},\"wordCount\":221,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MTYyNyM1ODUxNDQxIzIwOTk5MzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/\",\"name\":\"SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MTYyNyM1ODUxNDQxIzIwOTk5MzU=\",\"datePublished\":\"2023-10-02T18:32:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MTYyNyM1ODUxNDQxIzIwOTk5MzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MTYyNyM1ODUxNDQxIzIwOTk5MzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm - Market Newsdesk","og_description":"PHILADELPHIA, Oct. 02, 2023 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Prelude Therapeutics Inc. (NASDAQ: PRLD) (\u201cPrelude\u201d) on behalf of the company\u2019s investors. Since April 2023, shares of Prelude\u2019s common stock have declined in value from a trading price of over $8.00 per share to a current trading price of approximately $3.00 per share, a cumulative decline of over $5.00 per share, or 62% in value. The investigation seeks to determine whether the company\u2019s officers and\/or directors breached their fiduciary duties or violated the securities laws in connection with recent corporate actions. Prelude stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 \u2013 0750, or by &hellip; Continue reading \"SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2023-10-02T18:32:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyNyM1ODUxNDQxIzIwOTk5MzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm","datePublished":"2023-10-02T18:32:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/"},"wordCount":221,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyNyM1ODUxNDQxIzIwOTk5MzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/","name":"SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyNyM1ODUxNDQxIzIwOTk5MzU=","datePublished":"2023-10-02T18:32:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyNyM1ODUxNDQxIzIwOTk5MzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyNyM1ODUxNDQxIzIwOTk5MzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-kaskela-law-llc-announces-investigation-of-prelude-therapeutics-inc-nasdaq-prld-and-encourages-investors-to-contact-the-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/787454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=787454"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/787454\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=787454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=787454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=787454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}